Oral contraceptive use and venous thromboembolism: A consideration of the impact of bias and confounding factors on epidemiological studies

European Journal of Contraception and Reproductive Health Care

Volumn 1, Issue 1, 1996, Pages 21-30

  Rekers, H ^a   Norpoth, T ^b   Michaels, M A ^c  

^a NV ORGANON   (Netherlands)

^b BAYER PHARMA AG   (Germany)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

Bias; Confounding factors; Deep vein thrombosis; Epidemological studies; Oral contraceptives; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG UTILIZATION; EPIDEMIOLOGY; FEMALE; HUMAN; INCIDENCE; PATIENT REFERRAL; PREGNANCY; REVIEW; RISK; RISK FACTOR; STATISTICS; THROMBOEMBOLISM;

BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); CONTRACEPTIVES, ORAL, COMBINED; DRUG UTILIZATION; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HEALTHY WORKER EFFECT; HUMANS; INCIDENCE; ODDS RATIO; PREGNANCY; REFERRAL AND CONSULTATION; RISK FACTORS; THROMBOEMBOLISM;

EID: 0030088871     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189609150652     Document Type: Article

References (37)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8
3. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346: 1589-93
4. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-8
5. Lewis MA, Spitzer WO, Heinemann LAJ, et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90
6. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, et al. Enhancement of factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 1995; 346: 1593-6
7. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. Obstet Gynecol 1995; 15: 195-200
8. Farmer RDT. Letter to the Editor. Results of AAH Meditel Study. Lancet 1996; 347: 259
9. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-7
10. Vessey M, Mant D, Smith A, et al. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 1986; 292: 526
11. Royal College of General Practitioners. Oral Contraceptives and Health. An Interim Report from the Oral Contraceptive Study of the Royal College of General Practitioners. London: Pitman Medical, 1974; 43-50
12. Royal College of General Practitioners. Oral contraceptives, venous thrombosis, and varicose veins: Royal College of General Practitioners' Oral Contraception Study. J R Coll Gen Pract 1978; 28: 393-9
13. Graeff H, Battis, Hafter R, et al. Evaluation of hypercoagulability in users of oral contraceptives. Klin Wochenschr 1977; 55: 175-9
14. Bonnar J. Coagulation effects of oral contraceptives. Am J Obstet Gynecol 1987; 157: 1042-8
15. Meade TW, Haines AP, North WR, et al. Haemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen. Lancet 1977; 2: 948-51
16. Ball MJ, Ashwell E, Jackson M, et al. Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins. Contraception 1990; 41: 363-76
17. Kjaer A, Lebech AM, Borggaard B, et al. Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestel and gestodene. Contraception 1989; 40: 665-73
18. Melis GB, Fruzzetti F, Nicoletti I, et al. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991; 43: 23-31
19. Refn H, Kjaer A, Lebech AM, et al. Metabolic changes during treatment with two different progestogens. Am J Obstet Gynecol 1990; 163: 374-7
20. Sirtori CR, Calabresi L, Franceschini G, et al. Comparison of the lipoprotein and haemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women. Atherosclerosis 1990; 84: 203-11
21. Meinert CL. Clinical Trials - Design, Conduct and Analysis. New York: Oxford University Press, 1986; 65-70
22. Taubes G. Epidemiology faces its limits. Science 1995; 269: 164-9
23. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. J Am Med Assoc 1995; 274: 620-5
24. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. J Am Med Assoc 1995; 274: 654-5
25. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston: Little Brown & Co. 1987
26. Arrighi HM, Hertz-Picciotto I. The evolving concept of the healthy worker survivor effect. Epidemiology 1994; 5: 189-96
27. Farmer RDT, Lawrenson R. Utilization patterns of oral contraceptives in UK general practice. Contraception 1996; 54: 211-15
28. Poulter NR, Farley TMM, Chang CL, et al. Safety of combined oral contraceptive pills - Authors' reply. Lancet 1996; 347: 547
29. Sartwell PE, Masi AT, Arthes FG, et al. Thrombosis and oral contraceptives: a case control study. Am J Epidemiol 1969; 90: 365-80
30. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2: 651-7
31. Bottiger LE, Westerholm B. Oral contraceptives and thromboembolic disease. Acta Med Scand 1971; 190: 455-63
32. Reijnen HBM, Atsma WJ. Risk is highest during first months of use. Letter to the Editor. Br Med J 1995; 311: 1639
33. Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; in press
34. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (London) 1994; 369: 64-7
35. Koster T, Rosendaal FR, De Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6
36. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7
37. Vandenbroucke JP, Bloemenkamp KWM, Helmerhorst FM, et al. Safety of combined oral contraceptive pills - Authors' reply. Lancet 1996; 347: 547-8